Back to mobile site

Verrica (VRCA) Phase 2 Clinical Study of VP-102 in Patients with Common Warts Achieved Primary Endpoint

June 26, 2019 4:03 PM EDT Send to a Friend
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login